Loading...
Loading...
Watson Pharmaceuticals, Inc.
WPI today confirmed that its subsidiary, Watson Laboratories, Inc. -
Florida, filed an Abbreviated New Drug Application with the U.S. Food
and Drug Administration seeking approval to market Risedronate Sodium
Delayed-release Tablets, 35 mg. Watson's Risedronate Sodium Delayed-release
Tablets are a generic version of Warner Chilcott , LLC's Atelvia
delayed-release tablets. Atelvia is indicated for the treatment of
postmenopausal osteoporosis.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in